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Abstract
BACKGROUND: Nasopharyngeal carcinoma (NPC) is associated with Epstein–Barr virus infection as the main 
factor. Latent membrane protein (LMP)-1 protein and vascular endothelial growth factor (VEGF) have been 
suggested as the prognostic biomarker for NPC. 
AIM: This study is conducted to analyze the overexpression of LMP-1 protein and VEGF and the combination 
of these two in NPC patients. The role of LMP-1 protein in the induction of VEGF is identified by analyzing the 
association between these two proteins.
METHODS: A cross-sectional design study is conducted at Adam Malik General Hospital. Formalin-fixed, paraffin-
embedded sections from the NPC tissue samples are submitted for immunohistochemistry staining. Fisher’s exact 
test is used to analyze variables relation.
RESULTS: Among 56 samples, there was a significant correlation between LMP-1 protein overexpression with 
histopathological type and clinical staging, and VEGF overexpression with lymph node enlargement and clinical 
staging (p < 0.05). There was no significant correlation between LMP-1 protein with VEGF in NPC patients (p > 0.05).
CONCLUSION: Increased expressions of LMP-1 protein, VEGF, and a combination of LMP-1 protein and VEGF 
are noted in correlation with increasing the clinical stages. In contrast to the previously suggested hypotheses, the 
correlation between these two proteins is not significant in the present study. It could happen due to the different 
associations of each protein overexpression toward the clinical parameter. However, these two proteins could be 
used in evaluating the prognosis and providing a targeted therapy to NPC.
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Introduction
Nasopharyngeal carcinoma (NPC) is a rare 
disease with 85.000 cases and 50.000 death reported 
worldwide. It is an uncommon disease in the west but 
endemic in South China and Southeast Asia [1], [2]. 
GLOBOCAN 2012 showed that the incidence of NPC in 
Indonesia based on age-standardized rate was 8.3/100.000 
in male and 3.0/100.000 in female [3]. It is also known as 
a disease with a distinct geographical distribution. NPC 
arises from the epithelium of nasopharynx and the most 
location of the disease is in the fossa Rosenmüller [4].
Factors involved in progression of NPC are 
multifactorial including genetic, environment exposure, 
diet, geographic, and Epstein–Barr virus (EBV) 
infection. EBV infection is thought to be the main factor 
for pathogenesis of NPC [2], [4]. EBV latent infection 
express the EBV nuclear antigen, latent membrane 
protein (LMP)-1, LMP-2, EBV-encoded small RNAs, and 
miRNAs derived from BamHI-A rightward transcript [5].
In NPC cases, LMP-1 protein is expressed 
up to 65% among the cases. It has a great influence 
in gene expression and contribute to EBV-mediated 
tumorigenesis [2]. LMP-1 protein is known to activate 
several signaling pathways including NF-κB signaling 
pathway, MAPK pathways (Erk1/2, JNK, P38), STAT3, 
the PI3-kinase/Akt, and many others which contribute 
to the development of NPC [6], [7]. LMP-1 protein is 
involved in the promotion of cell motility, invasion, 
proliferation, lymph-angiogenesis, and epithelial 
mesenchyme transition [8].
Vascular endothelial growth factor (VEGF) is 
known as the most common growth factor responsible 
for tumorigenesis. It is involved in angiogenesis 
which is necessary in tumor growth by enhancing 
migration and proliferation of endothelium [9]. It is 
also known to be correlated with tumor stage, nodal 
involvement, and metastasis [10]. VEGF is known to 
be induced by LMP-1 protein along with the expression 
cyclooxygenase-2, epidermal growth factor receptor 
(EGFR), and other biomarkers that enhance cell 
 Chrestella et al. LMP-1 Protein Induction toward VEGF Expression in the Development of NPC
Open Access Maced J Med Sci. 2020 Mar 26; 8(B):368-374. 369
survival and proliferation [11]. LMP-1 protein and VEGF 
have been recognized as prognostic biomarkers for 
NPC. This study is conducted to identify the correlation 
between these two biomarkers and the implication of 
their expression on the clinicopathologic parameters of 
NPC patients. This will shed a light on the prognostic 
value of these proteins and may provide an insight to a 
targeted therapy for this aggressive carcinoma.
Methods
Patients and samples
The study was performed at Adam Malik 
General Hospital. Archives from the period 2016 to 
2017 were included in the study. Fifty-six paraffin blocks 
of previously biopsied and diagnosed NPCs were 
collected. The included samples were selected from 
patients with no other associated malignancies and with 
no prior chemo or radiotherapy. Immunohistochemistry 
staining is performed.
The variables of the study were LMP-1 protein 
expression, VEGF expression, primary tumor size (T), 
the presence of distant metastasis (M), lymph node 
enlargement (N), and clinical staging. We used the 
American Joint Committee on Cancer (AJCC) staging 
system 2010 to determine the cancer staging of the 
patients. Computer tomography scan with contrast 
was used to evaluate the primary tumor size and 
lymph node enlargement based on AJCC 2010. The 
histopathological type of cancer was determined based 
on the WHO criteria. The expression of LMP-1 protein 
and VEGF was evaluated by immunohistochemistry 
staining. The study has been approved by the Health 
Research Ethical Committee, Medical Faculty of 
Universitas Sumatera Utara/Adam Malik General 
Hospital, and the methods did not contradicted with the 
Declaration of Helsinki.
Immunohistochemistry staining
The paraffin blocks were cut into sections, 
deparaffinized and then rehydrated. Antigen retrieval 
performed in the Dako Epitope Retrieval and heated 
at 980°C for 15 min. The specimens were incubated 
with the primary antibody, anti-LMP-1 antibody, and 
anti-VEGF antibody. The tissues then were evaluated 
by two pathologists to identify the overexpression of 
LMP-1 protein and VEGF without knowing the clinical 
parameters of the patients.
Statistical analysis
All of the data gathered from the study were 
analyzed using the Statistical Package for the Social 
SciencesTM 23.0. We analyzed the correlation between 
the overexpression of LMP-1 protein, VEGF, and both 
of them with primary tumor, lymph node metastasis, 
and clinical staging evaluated using Fisher’s exact test. 
The correlation between LMP-1 protein and VEGF in 
NPC patients was also evaluated using Fisher’s exact 
test. The correlation is found if p < 0.05.
Results
The total samples in this study were 
56 samples of paraffin blocks of NPC biopsy. Table 1 
shows the demographic data of the samples based on 
distribution of age, sex, and WHO classification. The 
distribution of NPC patients based on age, sex, and 
WHO classification is shown in Table 1.
Table 1: Demographic distribution based on age, sex, and WHO 
classification
Characteristic n %
Age (years)
≤20 1 1.8
21–40 10 17.9
41–60 33 58.9
>60 12 21.4
Sex
Male 43 76.8
Female 13 23.2
WHO classification
WHO Type I 6 10.7
WHO Type II 42 75.0
WHO Type III 8 14.3
We found 42 samples (75.0%) were non-
keratinizing squamous cell carcinoma (WHO Type II) 
based on histopathological type. This is followed 
by undifferentiated carcinoma (WHO Type III) with 
eight samples (14.3%) and the least was keratinizing 
squamous cell carcinoma (WHO Type I) with six 
samples (10.7%).
The distribution of LMP-1 and VEGF expression 
based on clinical characteristics is shown in Table 2. 
LMP-1 protein was overexpressed in 47 samples (83.9%) 
and negative in nine. The overexpression of LMP-1 was 
highest in samples with WHO Type II with 40 samples 
(85.1%) and then followed by the WHO Type III with six 
samples (11.1%). The least occurrence was in the WHO 
Type I with just one sample (2.1%). The association of 
LMP-1 protein expression with histopathological type 
was found significant with p < 0.05.
This study showed that the overexpression 
of LMP-1 protein was the highest in the primary tumor 
T3 and T4 with 16 samples (34.0%) and followed with 
slight difference by primary tumor T2 with 12 samples 
(25.5%). The least was T1 with 3 samples (6.4%).
The overexpression of LMP-1 protein 
was highest in NPC patients with N3, which were 
20 samples (42.6%). The second highest occurrence 
of LMP-1 protein overexpression was found in N2 with 
15 samples (31.9%). The lowest was found in N1 and N0 
with seven samples (14.9%) and five samples (10.6%), 
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respectively. The overexpression of LMP-1 protein in 
patients with the presence of distant metastasis was 
found in high numbers of sample than the absence of 
it with 28 samples (59.6%) and 19 samples (40.4%), 
respectively.
Table 3: LMP-1 protein and VEGF expression in NPC
VEGF expression (%)
Positive Negative
LMP-1 protein 
expression
Positive 43 (84.3) 4 (80.0)
Negative 8 (15.7) 1 (20.0)
p=1.000*. *Fisher’s exact test. LMP-1: Latent membrane protein-1, VEGF: Vascular endothelial growth 
factor, NPC: Nasopharyngeal carcinoma.
As regards staging, there was no 
overexpression of LMP-1 protein in Stage I. The highest 
occurrence of LMP-1 protein overexpression was 
found in Stage IV with 28 samples (59.6%) and then 
followed by Stage III with 16 samples (34.0%). LMP-1 
protein overexpression was found in Stage II with three 
samples (6.4%). There was significant association of 
histopathological type and clinical staging with LMP-1 
protein overexpression with p < 0.05. There was no 
significant association of primary tumor size, lymph 
node enlargement, and distant metastasis with LMP-1 
protein overexpression.
VEGF was overexpressed in 51 samples 
(91.1%) and negative in five. The overexpression of 
VEGF was highest in samples with non-keratinizing 
squamous cell carcinoma with 39 samples (76.5%). The 
second highest was in undifferentiated carcinoma with 
seven samples (13.7%). The least was in keratinizing 
squamous cell carcinoma type with five samples (9.8%).
Based on primary tumor size, VEGF 
overexpression was the highest in T3 with 19 samples 
(37.3%). It then followed by T4 with 16 samples (31.4%), 
T2 with 12 samples (23.5%), and the least was T1 with 
four samples (7.8%).
VEGF overexpression in NPC patients in 
relation to the lymph node enlargement was found in 
N3 with 22 samples (43.1%). The second highest was 
found in N2 with 17 samples (33.3%). Then, it followed 
by N1 and N0 with seven samples (13.7%) and five 
samples (9.8%), respectively. There were 30 samples 
(58.8%) with the presence of distant metastasis in NPC 
patients with the overexpression of VEGF. It was higher 
than the patients with no distant metastasis which 
accounted for 21 samples (41.2%).
VEGF overexpression was highest in clinical 
Stage IV based on the staging group with 30 samples 
(58.8%). It then followed by Stage III with 17 samples 
(33.3%) and Stage II with four samples (7.8%). There 
was no found VEGF overexpression in clinical Stage 
I NPC patients. There was no significant correlation 
between histopathological type, primary tumor size, 
and the presence of distant metastasis with VEGF 
overexpression with p > 0.05. However, significant 
correlation was found between VEGF overexpression 
with lymph node enlargement and clinical staging with 
p < 0.05.
The dual expression of LMP-1 protein and 
VEGF overexpression was found in 43 samples (76.8%). 
Based on histopathological type, overexpression of both 
proteins was found highest in non-keratinizing squamous 
cell carcinoma with 37 samples (86.0%). This was 
followed by keratinizing squamous cell carcinoma and 
undifferentiated carcinoma with five samples (11.6%) and 
one sample (2.3%), respectively. A slight difference in 
LMP-1 expression was noticed in relation to the primary 
tumor size, T4 and T3 with 16 samples (37.2%) and 
15 samples (34.9%), respectively. The least expression 
was noticed in T2 with nine samples (20.9%) and T1 
with three samples (7.0%). As regard, the lymph node 
status, N3 was the most common for both LMP-1 protein 
and VEGF overexpression with 19 samples (44.2%), 
then followed by N2, N1, and N0 with 15 samples 
(34.9%), five samples (11.6%), and four samples (9.3%), 
respectively. The overexpression of both LMP-1 protein 
and VEGF was found highest in the presence of distant 
metastasis with 27 samples (62.8%), and higher than 
the patients without distant metastasis with 16 samples 
(37.2%). Clinical Stage IV was the highest occurrence 
Table 2: Expression of LMP-1 protein and VEGF according the to clinical characteristics of NPC
Characteristic LMP-1 protein and VEGF expression (%)
Over expression of combination 
of LMP-1 protein and VEGF
p-value Over expression of 
LMP-1 protein
p-value Over expression of 
VEGF
p-value Negative over 
expression
p-value
WHO classification <0.001* <0.001* 0.367* 0.107*
WHO type I 1 (2.3) 1 (2.1) 5 (9.8) 0 (0.0)
WHO type II 37 (86.0) 40 (85.1) 39 (76.5) 1 (100.0)
WHO type III 5 (11.6) 6 (11.1) 7 (13.7) 0 (0.0)
Primary tumor size 0.019* 0.091* 0.124* 0.089*
T1 3 (7.0) 3 (6.4) 4 (7.8) 1 (100.0)
T2 9 (20.9) 12 (25.5) 12 (23.5) 0 (0.0)
T3 15 (34.9) 16 (34.0) 19 (37.3) 0 (0.0)
T4 16 (37.2) 16 (34.0) 16 (31.4) 0 (0.0)
Lymph node 0.136* 0.656* 0.040* 0.125*
N0 4 (9.3) 5 (10.6) 5 (9.8) 1 (100.0)
N1 5 (11.6) 7 (14.9) 7 (13.7) 0 (0.0)
N2 15 (34.9) 15 (31.9) 17 (33.3) 0 (0.0)
N3 19 (44.2) 20 (42.6) 22 (43.1) 0 (0.0)
Distant metastasis 0.058*  0.272* 0.161* 0.446*
M0 16 (37.2) 19 (40.4) 21 (41.2) 1 (0.0)
M1 27 (62.8) 28 (59.6) 30 (58.8) 0 (0.0)
Stage grouping 0.001* 0.017* 0.008* 0.018*
I 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
II 1 (2.3) 3 (6.4) 4 (7.8) 0 (0.0)
III 15 (34.9) 16 (34.0) 17 (33.3) 0 (0.0)
IV 27 (62.8) 28 (59.6) 30 (58.8) 0 (0.0)
*Fisher’s exact test. LMP-1: Latent membrane protein-1, VEGF: Vascular endothelial growth factor, NPC: Nasopharyngeal carcinoma.
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for both of LMP-1 protein and VEGF overexpression with 
27 samples (62.8%). Stage III and Stage II accounted 
in 15 samples (34.9%) and one sample (2.3%), 
respectively, for the overexpression of LMP-1 protein 
and VEGF combination. There was no overexpression 
in the combination of both proteins in Stage I. There was 
significant association of histopathological type, primary 
tumor size, and clinical staging with the overexpression 
of the combination of LMP-1 protein and VEGF 
with p < 0.05. Fisher’s exact test in Table 3 showed there 
was no significant association between LMP-1 protein 
and VEGF in NPC patients (p > 0.05).
Discussion
LMP-1 protein is an oncoprotein expressed 
by EBV latent infection [5], [12]. It activates several 
signaling pathway including NF-κB, activator protein 
1 (AP-1), p38 MAPK, Janus-activated kinase/signal 
transducers, and activators of transcription pathways. 
This role of LMP-1 protein is associated with the 
tumorgenesis as well as metastasis and invasiveness 
of the cancer cells. Through the activation of NF-κB 
and AP-1, LMP-1 protein is thought to activate tumor 
growth factor-α (TGF-α) lead to EGFR activation and 
thus enhance proliferation of cells [13], [14]. It also 
alters function of tumor suppressor genes including 
p53 by MAPK pathway and RASSF1A, the most 
common inactivated tumor suppressor gene in NPC. 
LMP1 also plays a role in the down-regulation of p16. 
p16 plays a role in cell cycle checkpoint and activation 
of cyclin D1 which is an oncogene that plays a role 
in the development of cancer through stimulation of 
STAT3 and EGFR. LMP-1 protein can protect cells 
from apoptosis by activating NF-κB and STAT3 [14], 
[15], [16]. The study by You et al. revealed the role of 
LMP-1 protein in upregulating nuclear accumulation 
of β-catenin which needed for Wnt signaling pathway. 
β-catenin regulates the expression of genes which 
responsible for cancer including overexpression of 
cyclin D1 and downregulation of RASSF1A in NPC [17].
Role of LMP-1 protein in invasiveness and 
metastasis was taken in several mechanisms. It promotes 
metastasis by upregulating matrix-metalloproteinases-9 
which degrades extracellular matrix protein and 
upregulates VEGF as a proangiogenic factor for cancer 
cells [18]. LMP-1 protein, by upregulating β-catenin, 
is involved in invasive and metastasis of cells through 
downregulating the cell adhesion [17]. Activation of 
JAK/STAT and MAPK/ERK by LMP-1 protein also 
took parts in metastasis by altering cell-cell adhesion, 
matrix extracellular degradation, and enhanced motility 
and migration of NPC cells [19]. Downregulation of 
E-cadherin and overexpression of twist and snail, which 
induced by LMP-1 protein, alter the integrity of NPC 
cells. This process then lead to invasive and metastasis 
of cells [14]. LMP-1 protein induces hypoxia-inducible 
factor-1α which also increased cells motility lead to 
potentiation for invasiveness [20].
Our study revealed overexpression of LMP-1 
protein in 83.9% of cases. There was association of 
histopathological type and clinical staging with LMP-1 
protein overexpression in NPC patients. It supported by 
Wang et al. in their study which resulted 38 of 61 (62.3%) 
LMP-1 protein positive cases. Their study also revealed 
the significant association of LMP-1 protein expression 
with TNM stage/clinical staging [21]. The study by Li 
et al. showed the expression of LMP-1 protein in 24 of 
56 (43%) NPC patients. However, there was not found 
any significant association of LMP-1 protein expression 
with tumor value, N stage, and clinical stage in their 
study.
There were 36 of 40 (90%) patients which 
showed LMP-overexpression in study conducted by 
Borthakur et al. The association of histopathological 
type and the expression of LMP-1 protein was found 
in their study [22]. It was suggested that differentiation 
status of histopathological type associated with Wnt/β-
catenin signaling pathway activation. The recent was 
most found in the non-keratinizing squamous cell 
carcinoma type. This supported the result of our study 
which showed that the high expression of LMP-1 
protein was the highest in non-keratinizing squamous 
cell carcinoma [17].
The study by Rosales et al. showed just 10 
of 25 (40%) samples with positive LMP-1 protein 
expression and the significant association of older 
age and parapharyngeal space invasion with LMP-1 
protein expression. They suggested that LMP-1 protein 
expression may be associate with poorer prognosis in 
NPC patients [23]. Tabyaoui et al. in their study did not 
detect any overexpression of LMP-1 protein in NPC 
patients [24].
VEGF had others name such as vascular 
permeability factor or vascultropin. According to its 
name, it has mitogenic and angiogenic potentiation 
and allows the permeability of endothelial cells [25]. It 
is located on 6p21.3 chromosome and serves as the 
main growth stimulated factor in angiogenesis of tumor 
through migration and proliferation endothelial cells [9]. 
Its expression is regulated by several growth factors 
such as EGF, TGF-α, TGF-β, IL-1α, IL-1β, PGE2, IL-6, 
and IGF1 [26]. VEGF acts by binding to the receptor 
tyrosine kinase including VEGF receptor-1 (Flt-1) and 
VEGF receptor-2 (KDR/Flk-1) [27]. The binding of 
VEGF to its receptor promotes proliferation, survival, 
and motility of endothelial cells. The overexpression of 
VEGF has shown in most tumors, including NPC. It was 
known to have significant correlation with tumor stage, 
nodal involvement, and metastasis thus suggested 
as prognostic biomarker [10], [28]. It correlates with 
disease recurrences and poor prognosis of NPC [26].
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Our study shows the overexpression of VEGF 
in 51 of 56 (91.1%) samples. There is a significant 
correlation between VEGF overexpression with 
the lymph node status and clinical staging. These 
results are compatible with the study of Pan et al. 
resulted in VEGF overexpression in 66.7% of 111 
NPC patients. They also revealed that patients with 
overexpression of VEGF had worse prognosis than 
without VEGF overexpression. VEGF overexpression 
was an independent factor of non-metastasis for overall 
survival, disease- free survival, loco-regional control, 
and distant metastasis–free survival [27]. Study by Kim 
et al. showed the association of VEGF overexpression 
with high clinical staging (III and IV vs. I and II) and 
high nodal stage (N2 and N3 vs. N0 and N1). Their 
study also revealed there was not association of VEGF 
overexpression with worse prognosis [10]. However, 
Dan et al. revealed from their study that positive VEGF 
expression was independent prognostic factor in NPC. 
The overexpression of VEGF was found with proportion 
66.9% and was significantly associate with primary 
tumor, lymph node metastasis, and clinical stage [29].
Li et al. in their study showed the positive 
VEGF expression in 86 of 188 (45.7%) NPC cases. 
The correlation of VEGF expression with clinical stage, 
recurrence, and distant metastasis was significant, 
but not with T stage and lymph node metastasis. 
The 5-year survival rate of the VEGF overexpression 
was lower than patients with low expression in NPC 
patients. Their study resulted in association of VEGF 
overexpression with poor prognosis [9]. Study by 
Kurnianda et al. showed that the patients with VEGF 
overexpression had shorter survival rate than lower 
VEGF expression but the difference was not significant. 
It showed the expression of VEGF in 30 patients, with 
high overexpression in 11 patients and low expression 
in 19 patients [25].
Other studies also revealed the overexpression 
of VEGF in NPC patients and the association of it 
with clinicopathology parameter and poor prognosis. 
Study by Xinhua et al. showed the overexpression 
of VEGF in 60 of 86 (69.8%) NPC patients. Segawa 
et al. in their study revealed the overexpression of 
VEGF in 30 of 76 (39.5%) NPC cases. There was no 
significant association of primary tumor size, lymph 
node enlargement, and clinical staging with VEGF 
overexpression. The survival rate of NPC patients with 
overexpression of VEGF was shorter than patients 
without it and suggested VEGF as predictive marker in 
recurrence and metastasis of NPC [28], [30].
It was known that the association of 
LMP-1 protein with VEGF that it acts as inducers 
of VEGF [31], [32]. VEGF is expressed by LMP-1 
protein through the activation of JAK/STAT and MAPK/
ERK signaling pathway [19]. Promoter of VEGF has 
NF-κB and AP-1 sites which are the signaling pathway 
induced by LMP-1 protein. It provides the statement 
that VEGF upregulation may be the result of direct 
signaling by LMP-1 protein [13]. Our study resulted 
in there was association of combined LMP-1 protein 
and VEGF overexpression in NPC patients with the 
histopathological type, primary tumor size, and clinical 
staging. It came from the role of LMP-1 protein in 
differentiate histopathological type and promotes the 
metastasis and invasive of cancer cells along with VEGF. 
However, different from the known association of those 
two, we found that there was not significant association 
between LMP-1 protein and VEGF. We suggested it 
may be due to difference association of each with four 
clinicopathological parameter adjusted. Regardless of 
that, the combination of those two had relation with the 
clinicopathological of NPC patients, especially clinical 
stage. This result supports the role of LMP-1 protein 
and VEGF using as prognostic biomarker of NPC.
The majority of the cases in the study showed 
overexpression of LMP-1 and VEGF as well as dual 
reactivity to both markers. The overexpression of these 
was highest among non-squamous cell carcinoma 
cases, T3, N3, and Stage IV NPC. 
Conclusion
There were significant association of LMP-1 
protein overexpression with histopathological type and 
clinical staging, and VEGF overexpression with lymph 
node enlargement and clinical staging. There was a 
nonsignificant correlation between LMP-1 protein and 
VEGF overexpression. It is needed to do further research 
to identify the relation of LMP-1 protein and VEGF. More 
research is required to identify the correlation between 
the two markers. Furthermore, further work is needed 
to discover new targeted therapies for this aggressive 
carcinoma.
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